ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	TWD 14.90	-2.61%	30,551
29/10/26	TWD 15.30	-1.92%	52,653
28/10/26	TWD 15.60	+2.63%	24,156
27/10/26	TWD 15.20	-5.30%	93,330

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 30/10/2026			5-day change	1st Jan Change
14.90 ^TWD	-2.61%		-7.17%	-27.67%

16/10	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
12/08	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	1.07B 32.94M 29.5M 27.14M 24.59M 45.96M 3.13B 46.82M 324M 130M 1.65B 124M 121M 5.19B	P/E 2024	-11.3x	P/E 2025	-9.04x
Enterprise Value	1.02B 31.27M 28M 25.76M 23.34M 43.62M 2.97B 44.44M 307M 123M 1.56B 117M 115M 4.92B	EV / Sales 2024	35.4x	EV / Sales 2025	29.7x
Free-Float	28.72%	Yield 2024 *	-	Yield 2025	-

16/10	Duopharma Biotech Berhad Signs Five-Year Exclusive Distribution Agreement with Enimmune Corporation in Malaysia	CI
12/08	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09/04	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
13/08/25	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2025	CI
18/04/25	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/08/24	Enimmune corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
13/03/24	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/08/23	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023	CI
22/04/23	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/08/22	Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2022	CI
26/04/22	Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
14/08/21	Enimmune Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	CI
23/04/21	Enimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	CI

1 day	-2.61%
1 week	-7.17%
1 month	-7.74%
3 months	-4.49%
6 months	-21.37%
Current year	-27.67%

Enimmune corporation Stock

Stocks

6564

TW0006564008

Biotechnology & Medical Research

Valuation: Enimmune corporation

Chart: Enimmune corporation

Latest news: Enimmune corporation

Quotes and Performance

Price Extremes

Managers and Directors: Enimmune corporation

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	14.65	16.05
1 month	14.65	16.95
Current year	14.65	22.15
1 year	14.65	22.55
3 years	14.65	49.3
5 years	14.65	75.3
10 years	14.49	125

Manager	Title	Age	Since
Che Wei Chang CEO	Chief Executive Officer	-	07/01/2019
Ching Fen Yang CTO	Chief Tech/Sci/R&D Officer	-	21/07/2014
Hung Tun Chen AUD	Comptroller/Controller/Auditor	-	-

Director	Title	Age	Since
Chung Chi Li BRD	Director/Board Member	-	17/06/2020
Chung Cheng Liu CHM	Chairman	-	07/01/2019
Fei Pan BRD	Director/Board Member	-	02/01/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENIMMUNE CORPORATION	-2.61%	-7.17%	-28.19%	-59.57%	32.94M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+64.15%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+81.76%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+103.35%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+47.83%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+98.80%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+866.21%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+96.58%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+46.95%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+349.24%	24.7B
Average	+0.04%	+6.07%	+40.00%	+169.53%	39.44B
Weighted average by Cap.	+0.18%	+5.44%	+47.99%	+176.65%

	2024	2025
Net sales	39.92M 1.22M 1.1M 1.01M 913K 1.71M 116M 1.74M 12.02M 4.82M 61.1M 4.59M 4.49M 193M	48.19M 1.48M 1.32M 1.22M 1.1M 2.06M 140M 2.1M 14.51M 5.82M 73.77M 5.54M 5.43M 233M
Net income	-158M -4.83M -4.32M -3.98M -3.6M -6.74M -458M -6.86M -47.43M -19.04M -241M -18.12M -17.73M -761M	-164M -5.04M -4.51M -4.15M -3.76M -7.03M -478M -7.16M -49.48M -19.86M -252M -18.9M -18.5M -793M
Net Debt	-382M -11.71M -10.48M -9.64M -8.74M -16.33M -1.11B -16.64M -115M -46.17M -585M -43.94M -43M -1.84B	-54.59M -1.67M -1.5M -1.38M -1.25M -2.33M -159M -2.38M -16.44M -6.6M -83.57M -6.28M -6.15M -264M